Healthcare is undergoing a profound transformation, one that’s being shaped by the convergence of two of the most powerful technological forces of our time: Biotechnology and Artificial Intelligence (AI). On their own, each field has sparked scientific revolutions. But together, they are fundamentally redefining how we understand, prevent, diagnose,
United Kingdom, October 6, 2025: AstraZeneca has entered into a licensing agreement worth up to $555 million with Algen Biotechnologies, a U.S.-based biotech firm that leverages artificial intelligence for gene-editing discoveries. Under the deal, AstraZeneca will gain exclusive rights to develop and commercialize therapies discovered through Algen’s
Ras Al Khaimah, 01-oct-2025: Biostadt India Limited, a global frontrunner in biostimulant solutions, has announced plans to set up a state-of-the-art manufacturing hub in Ras Al Khaimah’s Al Hulaila Industrial Zone. The agreement for the 100,000 sq ft site was formalized between Anas Hijjawi, Chief Commercial Officer of
Biotechnology continues to be a driving force in modern science, with red biotechnology standing out for its transformative role in medical research and patient care. As diseases evolve, healthcare demands increase, and innovation accelerates, there is a growing need for global platforms where ideas, research, products, and people can converge.
United Kingdom, 16-sept-2025: Hundreds of patients with a fast-growing form of lung cancer will soon gain access to a new treatment, after the National Institute for Health and Care Excellence (NICE) approved the use of durvalumab, also known as Imfinzi, on the NHS. The immunotherapy, developed by AstraZeneca, has been